BLIS M18® (Streptococcus salivarius for Oral Health — Stratum Nutrition)

Evidence Level
Strong
1 Clinical Trial
6 Documented Benefits
4/5 Evidence Score

BLIS M18® is a PROPRIETARY STREPTOCOCCUS SALIVARIUS PROBIOTIC STRAIN developed by Blis Technologies and distributed by Stratum Nutrition — distinguished by specific oral health applications targeting teeth and gums. Complementary to BLIS K12 (which targets ENT). Produces BLIS targeting cariogenic and periodontal pathogens. Used for: dental health, gum health, plaque reduction, oral microbiome balance, dental hygiene adjunct.

Studied Dose 1 billion CFU/day BLIS M18 (research-validated)
Active Compound Streptococcus salivarius M18 (proprietary strain producing salivaricin M)

Benefits

Dental Health Support

BLIS M18 colonizes oral cavity and supports tooth health — produces bacteriocins targeting cariogenic bacteria including Streptococcus mutans (primary cavity-causing bacteria).

Gum Health Adjunct

Modulates oral microbiome supporting healthy gums; complementary to dental hygiene practices.

Plaque Reduction

Some BLIS M18 trials demonstrate reduced dental plaque accumulation.

Oral Microbiome Balance

Establishes beneficial Streptococcus salivarius population reducing pathogenic bacteria.

Streptococcus mutans Inhibition

Specifically targets S. mutans (primary cavity-causing organism) via salivaricin M production.

Adjunct to Dental Hygiene

Used in conjunction with regular brushing, flossing, dental visits — enhances rather than replaces traditional dental care.

Mechanism of action

1

Oral Cavity Colonization

S. salivarius M18 colonizes oral cavity competing with pathogenic bacteria for niches.

2

Salivaricin M Production

Produces salivaricin M — bacteriocin targeting S. mutans (primary cavity-causing bacteria).

3

Cariogenic Bacteria Inhibition

Reduces populations of S. mutans, S. sobrinus, and other cavity-causing bacteria.

4

Enzyme Production

Produces enzymes that may support oral cavity homeostasis.

Clinical trials

1
BLIS M18 for Dental Health — Multiple RCTs
PubMed

Multiple BLIS M18 RCTs on dental health markers including S. mutans counts, plaque, gum health.

Children and adults.

Reduced S. mutans counts; supports dental health markers.

About this ingredient

About the active ingredient

BLIS M18 is a PROPRIETARY STREPTOCOCCUS SALIVARIUS PROBIOTIC STRAIN developed by BLIS TECHNOLOGIES — distinguished from BLIS K12 by specific oral/dental health applications.

KEY DISTINCTIONS: (1) DENTAL HEALTH FOCUS (vs K12 ENT focus); (2) Targets S. MUTANS (cavity-causing); (3) Produces SALIVARICIN M; (4) Complementary to BLIS K12; (5) Dairy-free version available; (6) Distributed by Stratum Nutrition.

EVIDENCE-BASED USES: (1) Dental health; (2) Gum health adjunct; (3) Plaque reduction; (4) Oral microbiome balance; (5) Dental hygiene adjunct; (6) Cavity prevention support.

CRITICAL CAUTIONS: (1) ADJUNCT NOT REPLACEMENT — BLIS M18 supports dental hygiene; does NOT replace brushing, flossing, dental visits; (2) DAIRY ALLERGY — use dairy-free version; (3) IMMUNOCOMPROMISED — caution; consult; (4) ANTIBIOTICS — separate timing; (5) DOSE — 1 billion CFU/day; (6) DELIVERY FORMAT — lozenges or chewable for oral cavity colonization; (7) BLIS M18 vs BLIS K12 — M18 dental, K12 ENT; complementary; can be used together; (8) BLIS M18 vs DENTAL HYGIENE PRODUCTS — adjunct to traditional care; modulates microbiome differently than antimicrobial mouthwash; (9) FOR COMPREHENSIVE DENTAL HEALTH — twice-daily brushing, daily flossing, regular dental visits, balanced diet, BLIS M18 adjunct; (10) BRAND VERIFICATION — BLIS M18 is Blis Technologies trademark; specific patented strain.

Side effects and drug interactions

Common Potential side effects

Generally extremely well-tolerated.
Mild GI distress (rare).
Allergic reactions extremely rare.
DAIRY allergen in original version — dairy-free version now available.
BACTEREMIA RISK in IMMUNOCOMPROMISED — theoretical risk with all live probiotics; consult.

Important Drug interactions

Antibiotics — kills probiotic; separate timing.
Immunosuppressants — caution; consult.
Pregnancy — generally safe; consult.
Lactation — generally safe.
Children — established pediatric safety.
DAIRY ALLERGY — use dairy-free version.

Frequently asked questions about BLIS M18® (Streptococcus salivarius for Oral Health — Stratum Nutrition)

What is the recommended dosage of BLIS M18® (Streptococcus salivarius for Oral Health — Stratum Nutrition)?

The clinically studied dose for BLIS M18® (Streptococcus salivarius for Oral Health — Stratum Nutrition) is 1 billion CFU/day BLIS M18 (research-validated). Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is BLIS M18® (Streptococcus salivarius for Oral Health — Stratum Nutrition) used for?

BLIS M18® (Streptococcus salivarius for Oral Health — Stratum Nutrition) is studied for dental health support, gum health adjunct, plaque reduction. BLIS M18 colonizes oral cavity and supports tooth health — produces bacteriocins targeting cariogenic bacteria including Streptococcus mutans (primary cavity-causing bacteria).

Are there side effects from taking BLIS M18® (Streptococcus salivarius for Oral Health — Stratum Nutrition)?

Reported potential side effects may include: Generally extremely well-tolerated. Mild GI distress (rare). Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does BLIS M18® (Streptococcus salivarius for Oral Health — Stratum Nutrition) interact with medications?

Known drug interactions may include: Antibiotics — kills probiotic; separate timing. Immunosuppressants — caution; consult. Consult a pharmacist or healthcare provider if you take prescription medications.

Is BLIS M18® (Streptococcus salivarius for Oral Health — Stratum Nutrition) good for immune support?

Yes, BLIS M18® (Streptococcus salivarius for Oral Health — Stratum Nutrition) is researched for Immune Support support. BLIS M18 colonizes oral cavity and supports tooth health — produces bacteriocins targeting cariogenic bacteria including Streptococcus mutans (primary cavity-causing bacteria).